TB Research

Pulmonary cavitary disease due to Mycobacterium xenopi

Yousri Ben Abdallah, Nabil Belfeki, Timothée Klopfenstein, Souheil Zayet

Infectious Medicine · 2022-01

Abstract

Non-tuberculous mycobacteria are a significant cause of pulmonary infections worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has a low pathogenicity and usually requires immunosuppression or lung diseases. We describe herein a scarce case of pulmonary cavitary disease attributed to M. xenopi in a 57-year-old Caucasian patient with underlying structural lung disease successfully treated with rifampicin, ethambutol, clarithromycin, and amikacin.

MeSH terms

  • Ethambutol
  • Medicine
  • Rifampicin
  • Amikacin
  • Clarithromycin
  • Immunosuppression
  • Mycobacterium avium complex
  • Lung
  • Antimycobacterial
  • Disease
  • Tuberculosis
  • Mycobacterium tuberculosis
  • Internal medicine